Sign Up
Stories
ARMGO Pharma Receives $1 Million Award for Muscle Dystrophy Treatment
Share
ARMGO Pharma's Positive Trial Results
Dyne Therapeutics' Promising Year Ahead
Edgewise Launches Dedicated Website for ...
Overview
API
ARMGO Pharma, in collaboration with the Muscular Dystrophy Association, has received a $1 million award for preclinical work on ARM210, a potential treatment for Duchenne muscular dystrophy. The Rycal drug targets the ryanodine receptor to repair calcium leaks in muscle disease. ARMGO Pharma is dedicated to developing small-molecule therapeutics for cardiac, musculoskeletal, and neurological disorders, with its lead Rycal program, ARM036, in phase 2 clinical studies for heart failure and arrhythmias. Les Laboratoires Servier holds development and commercial rights for ARMGO's Rycal drugs outside of the U.S. and Japan.
Ask a question
How does the partnership with Les Laboratoires Servier influence the global distribution and accessibility of ARMGO Pharma's Rycal drugs?
How might the successful development of ARM210 impact the treatment landscape for Duchenne muscular dystrophy?
What are the potential implications of ARMGO Pharma's collaboration with the Muscular Dystrophy Association and the National Institute of Neurological Disorders and Stroke?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Oct 2023
Nov 2023
Dec 2023
Jan 2024
Coverage
mda.o